Contemporary OB/GYN week in review: Pregnancy prevention, postpartum depression, and more

News
Article

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Contemporary OB/GYN week in review: Pregnancy prevention, postpartum depression, and more

Contemporary OB/GYN week in review: Pregnancy prevention, postpartum depression, and more

Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, July 22 - Friday, July 26, 2024), and click each link to read and watch anything you may have missed.

1.) FDA approves femlyv as the first orally disintegrating tablet for pregnancy prevention

Femlyv, containing norethindrone acetate and ethinyl estradiol, offers a new oral contraceptive option for individuals with swallowing difficulties, expanding access and convenience.

Click here for the full article.

2.) First patient dosed in RECONNECT trial of RE104 for postpartum depression

Reunion Neuroscience Inc. initiates phase 2 trial of RE104, a novel short-duration psychedelic treatment for postpartum depression, aiming to provide rapid and effective relief for affected mothers.

Click here for the full article.

3.) Unexpected RBC antibodies found in 1.85% of pregnant women

A recent study reveals that unexpected red blood cell antibodies are present in 1.85% of pregnant women, highlighting the need for potential interventions to manage fetal anemia.

Click here for the full article.

4.) ZY5301 tablet effective for chronic pelvic pain

These results indicated a significant reduction of CPP from 12 weeks of ZY5301 treatment. Investigators recommended a ZY5301 600 mg/d dose be investigated in a phase 3 trial.

Click here for the full article.

5.) ACOG release new practice update on biomarker testing for hypertensive disorders in pregnancy

Padmashree Woodham, MD, professor of maternal-fetal medicine at Wellstar Medical College of Georgia Health, outlines the new ACOG practice update on biomarker testing for risk assessment of hypertensive disorders in pregnancy.

Click here for the full article.

Recent Videos
March of Dimes 2024 Report highlights preterm birth crisis | Image Credit: marchofdimes.org
Understanding and managing postpartum hemorrhage: Insights from Kameelah Phillips, MD | Image Credit: callawomenshealth.com
Understanding cardiovascular risk factors in women | Image Credit: cedars-sinai.org.
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Lauren Streicher, MD
March of Dimes reports increase in maternity care desert prevalence | Image Credit: marchofdimes.org.
Evaluating a miniature robotic device for hysterectomy | Image Credit: linkedin.com.
Discussing low-dose aspirin use for preeclampsia prevention | Image Credit: komodohealth.com
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
Related Content
© 2024 MJH Life Sciences

All rights reserved.